克雷西隆公司的植物性静血凝TRAUMAGEL获得FDA的批准, 
Cresilon's plant-based hemostatic gel TRAUMAGEL receives FDA clearance for life-threatening bleeding control.
布鲁克林的Cresilon Inc., 一家专门生产止血医疗器械的生物技术公司, 已获得FDA的批准, Brooklyn-based Cresilon Inc., a biotech company specializing in hemostatic medical devices, has received FDA clearance for its plant-based hemostatic gel, TRAUMAGEL, designed to control life-threatening bleeding in seconds. TROMAGEL针对美国军方、政府卫生机构、紧急医疗系统以及遭受创伤的医疗专业人员的需要。 TRAUMAGEL targets the needs of the U.S. military, government health agencies, EMS systems, and medical professionals who encounter traumatic wounds. 这标志着Cresilon第二次获得FDA对人类使用的批准. This marks Cresilon's second FDA clearance for human use.
